ReviewInternational journal of molecular sciences2016
Oridonin, a Promising ent-Kaurane Diterpenoid Lead Compound.
Review in International journal of molecular sciences, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 79 citations in OpenAlex.
- Oridonin Suppresses Bladder Cancer Growth and Metastasis by Inducing S-Phase Arrest and Apoptosis.International journal of molecular sciences · 2026Article
- Integrative network pharmacology, molecular dynamics simulation, and single-cell RNA sequencing strategies reveal the multi-target mechanisms of oridonin against cervical cancer.Frontiers in pharmacology · 2026Article
- NLRP3 inflammasome in neuroinflammation and central nervous system diseases.Cellular & molecular immunology · 2025Review
- Research progress and molecular mechanism of oridonin in the treatment of malignant melanoma.Frontiers in oncology · 2025Review
- Semisynthesis and Antitumour Evaluation of Natural Derivatives fromInternational journal of molecular sciences · 2024Article
- Synthesis and Application of a pH-Responsive Functional Metal-Organic Framework: In Vitro Investigation for Delivery of Oridonin in Cancer Therapy.Molecules (Basel, Switzerland) · 2024Article
- Oridonin fromFood science & nutrition · 2024Review
- Antibacterial Mechanisms and Antivirulence Activities of Oridonin against PathogenicMicroorganisms · 2024Article
- Enhancing cancer therapy: advanced nanovehicle delivery systems for oridonin.Frontiers in pharmacology · 2024Review
- Recent advances in oridonin derivatives with anticancer activity.Frontiers in chemistry · 2023Review
- A Powerful Tool in the Treatment of Myocardial Ischemia-Reperfusion Injury: Natural and Nanoscale Modified Small Extracellular Vesicles Derived from Mesenchymal Stem Cells.International journal of nanomedicine · 2023Review
- Phenols and terpenoids: natural products as inhibitors of NLRP3 inflammasome in cardiovascular diseases.Inflammopharmacology · 2022Review
- Preparation, Characterization, and Evaluation of Liposomes Containing Oridonin fromMolecules (Basel, Switzerland) · 2022Article
- Evolving Roles of Natural Terpenoids From Traditional Chinese Medicine in the Treatment of Osteoporosis.Frontiers in endocrinology · 2022Review
- Oridonin Promotes Apoptosis and Restrains the Viability and Migration of Bladder Cancer by Impeding TRPM7 Expression via the ERK and AKT Signaling Pathways.BioMed research international · 2021Article
- Oridonin Prolongs the Survival of Mouse Cardiac Allografts by Attenuating the NF-κB/NLRP3 Pathway.Frontiers in immunology · 2021Article
- Plant-Derived Chinese Medicine Monomers on Ovarian Cancer via the Wnt/Journal of oncology · 2021Review
- The Effect of Terpenoid Natural Chinese Medicine Molecular Compound on Lung Cancer Treatment.Evidence-based complementary and alternative medicine : eCAM · 2021Review
- Promising Therapeutic Candidate for Myocardial Ischemia/Reperfusion Injury: What Are the Possible Mechanisms and Roles of Phytochemicals?Frontiers in cardiovascular medicine · 2021Review
- NLRP1 and NLRP3 inflammasomes as a new approach to skin carcinogenesis.Oncology letters · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oridonin belongs to ent-kaurane tetracyclic diterpenoid and was first isolated from Isodon species. It exhibits inhibitory activities against a variety of tumor cells, and pharmacological study shows that oridonin could inhibit cell proliferation, DNA, RNA and protein synthesis of cancer cells, induce apoptosis and exhibit an antimutagenic effect. In addition, the large amount of the commercially-available supply is also very important for the natural lead oridonin. Moreover, the good stability, suitable molecular weight and drug-like property guarantee its further generation of a natural-like compound library. Oridonin has become the hot molecule in recent years, and from the year 2010, more than 200 publications can be found. In this review, we summarize the synthetic medicinal chemistry work of oridonin from the first publication 40 years ago and share our research experience of oridonin for about 10 years, which may provide useful information to those who are interested in this research field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.